Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/128157
Title: | Non-inferiority of dose reduction versusstandard dosing of TNF-inhibitors in axial spondyloarthritis |
Author: | Gratacós, Jordi Pontes García, Caridad Juanola, Xavier Sanz, Jesús Torres, Ferran Avendaño, Cristina Vallano Ferraz, Antonio Calvo Rojas, Gonzalo De Miguel, Eugenio Sanmartí Sala, Raimon REDES-TNF Investigators |
Keywords: | Espondiloartropaties Administració de medicaments Posologia Citoquines Spondyloarthropathies Administration of drugs Posology Cytokines |
Issue Date: | 8-Jan-2019 |
Publisher: | BioMed Central |
Abstract: | Objective: the objective was to determine if dose reduction is non-inferior to full-dose TNFi to maintain low disease activity (LDA) in patients already in remission with TNFi, in axial spondyloarthritis. Methods: randomized, parallel, non-inferiority, open-label multicentre clinical trial. Patients were eligible if they had axial spondyloarthritis and had been in clinical remission for ≥ 6 months with any available TNFi (adalimumab, etanercept, infliximab, golimumab) at the dose recommended by product labelling. Patients were randomized by automated central allocation to continue the same TNFi dose schedule, or to reduce the dose by roughly half according to the protocol. The main outcome was the proportion of subjects with LDA after 1 year. Serious adverse reactions or infections were recorded. Results: the trial stopped due to end of the funding period, after 126 patients were randomized; 113 patients (84.1% male, mean age (SD) 45.6 (13.0) years) were included in the main per-protocol subset. Non-inferiority was concluded for LDA at 1 year (47/55 (83.8%) patients in the full-dose and 48/58 (81.3%) patients in the reduced-dose arm, adjusted difference (95% CI) − 2.5% (− 16.6% to 11.7%)). Serious adverse reactions or infections were reported in 7/62 patients (11.3%) assigned to full dose and 2/61 patients (3.3%) assigned to reduced dose (p value = 0.164). Conclusion: in patients with ankylosing spondylitis in clinical remission for at least 6 months, dose reduction is non-inferior to full TNF inhibitor doses to maintain LDA after 1 year. Serious adverse events may be less frequent with reduced doses. |
Note: | Reproducció del document publicat a: https://doi.org/10.1186/s13075-018-1772-z |
It is part of: | Arthritis Research & Therapy, 2019, vol. 21, p. 11 |
URI: | http://hdl.handle.net/2445/128157 |
Related resource: | https://doi.org/10.1186/s13075-018-1772-z |
ISSN: | 1478-6362 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Patologia i Terapèutica Experimental) Articles publicats en revistes (Fonaments Clínics) Articles publicats en revistes (Medicina) Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
684287.pdf | 1.43 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License